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Abstract
Introduction: Endometrial	hyperplasia	may	be	either	a	benign	proliferation	or	a	pre‐
malignant	lesion.	In	order	to	differentiate	these	two	conditions,	two	possible	histo‐
logic	classifications	can	be	used:	the	World	Health	Organization	(WHO)	classification	
and	the	endometrial	intraepithelial	neoplasia	(EIN)	classification.	The	2017	European	
Society	of	Gynaecological	Oncology	guidelines	recommend	the	use	of	immunohisto‐
chemistry	for	tumor	suppressor	protein	phosphatase	and	tensin	homolog	(PTEN)	to	
improve	 the	 differential	 diagnosis.	Nonetheless,	 its	 diagnostic	 accuracy	 has	 never	
been	defined.	We	aimed	to	assess	the	diagnostic	accuracy	of	immunohistochemistry	
for	PTEN	in	the	differential	diagnosis	between	benign	and	premalignant	endometrial	
hyperplasia.
Material and methods: Electronic	databases	were	searched	from	their	inception	to	
May	2018	for	studies	assessing	immunohistochemical	expression	of	PTEN	in	endo‐
metrial	hyperplasia	specimens.	PTEN	status	(“loss”	or	“presence”)	was	the	index	test;	
histological	 diagnosis	 (“precancer”	 or	 “benign”)	 was	 the	 reference	 standard.	
Sensitivity,	specificity,	positive	and	negative	 likelihood	ratios	 (LR+,	LR−),	diagnostic	
odds	ratio	 (DOR),	and	area	under	the	curve	 (AUC)	on	summary	receiver	operating	
characteristic	curves	were	calculated	(95%	CI),	with	a	subgroup	analysis	based	on	the	
histologic	classification	adopted	(WHO	vs	EIN).
Results: Twenty‐seven	observational	studies	with	1736	cases	of	endometrial	hyper‐
plasia	were	included.	Pooled	estimates	showed	low	diagnostic	accuracy:	sensitivity	
54%	(95%	CI	50%‐59%),	specificity	66%	(63%‐69%),	LR+	1.55	(1.29‐1.87),	LR−	0.72	
(0.62‐0.83),	DOR	3.56	(2.02‐6.28),	AUC	0.657.	When	the	WHO	subgroup	was	com‐
pared	with	the	EIN	subgroup,	higher	accuracy	(AUC	0.694	vs	0.621),	and	higher	het‐
erogeneity	in	all	analyses,	were	observed.
Conclusions: Immunohistochemistry	for	PTEN	showed	low	diagnostic	usefulness	in	
the	differential	diagnosis	between	benign	and	premalignant	endometrial	hyperplasia.	
In	 the	 absence	 of	 further	 evidence,	 the	 recommendation	 about	 its	 use	 should	 be	
reconsidered.
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1  | INTRODUCTION
Endometrial	 hyperplasia	 (EH)	 is	 an	 irregular	 proliferation	 of	 endo‐
metrial	glands	with	increased	gland	to	stroma	ratio	when	compared	
with	the	normal	proliferative	endometrium.1	It	may	be	a	benign	con‐
dition	caused	by	an	unopposed	action	of	estrogens	or	a	precancer‐
ous	process.2,3
It	 is	necessary	to	distinguish	between	these	two	conditions.	 In	
fact,	premalignant	EH	requires	total	hysterectomy,	or	a	conservative	
progestin‐based	therapy	with	close	follow	up	in	selected	women.	On	
the	other	hand,	benign	EH	may	be	managed	with	observation	alone,	
or	with	progestins	when	symptomatic.4,5
Two	different	 systems	have	been	proposed	 to	classify	EH:	 the	
World	Health	Organization	(WHO)	system	and	the	endometrial	in‐
traepithelial	neoplasia	(EIN)	system.2,3
The	 WHO	 system	 distinguishes	 “EH	 without	 atypia”	 (benign)	
from	 “atypical	 EH”	 (premalignant)	 based	on	 the	 presence	of	 cyto‐
logic	atypia.1,2
The	EIN	system	distinguishes	“benign	EH”	from	“endometrial	in‐
traepithelial	neoplasia”	based	on	a	combination	of	histologic	criteria.	
The	EIN	system	may	also	be	applied	objectively	through	a	comput‐
erized	morphometric	analysis;	such	analysis	allows	calculation	of	the	
“morphometric	D‐score,”	which	 subdivides	EH	 into	 “high/interme‐
diate	 risk”	 (D‐score	 [D]	≤	1)	 or	 “low	 risk”	 (D	>	1)	 of	 progression	 to	
cancer.2,3
In	the	revised	2014	WHO	classification,	the	terms	“atypical	EH”	
and	EIN	are	reported	as	synonyms,	although	EIN	refers	to	“endome‐
trioid	intraepithelial	neoplasia.”1
The	histologic	evaluation	is	considered	the	gold	standard	in	the	
differential	 diagnosis	 between	 benign	 and	 premalignant	 EH.	 The	
WHO	system	is	recommended	by	the	Royal	College	of	Obstetricians	
and	 Gynaecologists,	 whereas	 the	 EIN	 system	 is	 recommended	
by	 the	 American	 College	 of	 Obstetricians	 and	 Gynecologists.4,5 
Nonetheless,	 histologic	 classifications	may	 be	 affected	 by	 several	
problems,	 such	 as	 low	 reproducibility,	 tissue	 inadequacy,	 artefact	
changes,	or	ambiguous	features.3,6
To	 improve	 the	 reliability	 of	 the	 differential	 diagnosis,	 several	
diagnostic	markers	have	been	proposed.	Great	emphasis	has	been	
given	 to	 the	 loss	 of	 expression	 of	 the	 tumor	 suppressor	 protein	
phosphatase	 and	 tensin	homolog	 (PTEN),2,7	 because	 the	mutation	
of	 PTEN	 is	 the	 most	 common	 molecular	 alteration	 found	 in	 en‐
dometrial	 carcinogenesis8,9	 and	 occurs	 in	 an	 early	 phase.7,9	 In	 the	
2017	European	Society	of	Gynaecological	Oncology	(ESGO)	guide‐
lines	 (based	on	the	2016	European	Society	for	Medical	Oncology‐
ESGO‐European	Society	 for	Radiotherapy	&	Oncology	Consensus	
Conference),	 the	 immunohistochemical	 assessment	 of	 PTEN	
expression	is	recommended	to	recognize	endometrial	precancerous	
lesions.10	In	spite	of	this,	the	several	studies	in	the	literature	showed	
a	highly	variable	degree	of	association	between	loss	of	PTEN	expres‐
sion	and	premalignant	EH,	missing	an	analysis	of	diagnostic	accuracy.	
The	actual	usefulness	of	immunohistochemistry	for	PTEN	has	never	
been	defined.
The	aim	of	this	study	was	to	determine	the	diagnostic	accuracy	
of	immunohistochemical	assessment	of	PTEN	in	differential	diagno‐
sis	between	benign	and	premalignant	EH,	by	extracting	data	 from	
the	available	literature.
2  | MATERIAL AND METHODS
This	study	was	performed	according	to	a	protocol	recommended	for	
systematic	review	and	meta‐analysis.	The	protocol	defining	methods	
for	collecting,	extracting,	and	analyzing	data	was	designed	a	priori.	
All	stages	were	conducted	independently	by	two	reviewers	(AR,	AT).	
The	two	authors	independently	assessed	electronic	search,	eligibil‐
ity	of	the	studies,	inclusion	criteria,	risk	of	bias,	data	extraction,	and	
data	 analysis.	 Disagreements	 were	 resolved	 by	 discussion	 with	 a	
third	reviewer	(GS).
The	study	was	reported	following	the	Preferred	Reporting	Item	
for	 Systematic	 Reviews	 and	Meta‐analyses	 (PRISMA)	 statement11 
and	 the	 Synthesizing	 Evidence	 from	 Diagnostic	 Accuracy	 Tests	
(SEDATE)	guideline.12
Searches	 were	 conducted	 using	 MEDLINE,	 EMBASE,	 Web	 of	
Sciences,	 Scopus,	 ClinicalTrial.gov,	 OVID,	 Cochrane	 Library,	 and	
Google	Scholar	as	electronic	databases.	The	relevant	articles	were	
searched	from	their	inception	to	May	2018	using	a	combination	of	
the	following	text	words	and	all	their	synonyms	found	in	the	Medical	
SubHeading	 (MeSH)	vocabulary:	 “endometrial	hyperplasia”;	 “endo‐
metrial	intraepithelial	neoplasia”;	“EIN”;	“precancer”;	“premalignant”;	
“precursor”;	 “PTEN”;	 “phosphatase	 and	 tensin	homolog”;	 “marker”;	
“biomarker”;	 “diagnosis”	 “immunohistochemistry”;	 “immunohisto‐
chemical”.	Review	of	articles	also	included	the	abstracts	of	all	refer‐
ences	retrieved	from	the	search.
K E Y WO RD S
atypical	endometrial	hyperplasia,	biomarker,	cancer	precursor,	endometrial	hyperplasia	
without	atypia,	endometrial	intraepithelial	neoplasia,	endometrioid	adenocarcinoma,	
phosphatase	and	tensin	homolog
Key message
Immunohistochemistry	 for	PTEN	has	 low	diagnostic	use‐
fulness	in	differentiating	benign	from	premalignant	endo‐
metrial	 hyperplasia.	Hence,	 its	 recommended	use	 should	
be reconsidered.
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All	 peer‐reviewed	 retrospective	 or	 prospective	 studies	 assess‐
ing	 the	 immunohistochemical	 expression	 of	 PTEN	 on	 histological	
specimens	 of	 premalignant	 EH	 (atypical	 EH/endometrial	 intraepi‐
thelial	neoplasia)	or	benign	EH	(EH	without	atypia/benign	EH)	were	
included	in	the	systematic	review.
Exclusion	criteria	were:
1.	 data	 on	 PTEN	 expression	 not	 extractable;
2.	 no	distinction	between	premalignant	and	benign	EH;
3.	 case	reports	and	reviews;
4.	 patient	data	overlapping	with	a	study	already	included.
Only	the	studies	assessing	both	premalignant	and	benign	EH	were	
included	in	the	meta‐analysis.
According	 to	 the	 revised	 Quality	 Assessment	 of	 Diagnostic	
Accuracy	Studies	(QUADAS‐2),13	four	domains	related	to	risk	of	bias	
were	assessed	in	each	study:	(1)	patient	selection	(low	risk	if	the	pa‐
tients	were	selected	as	consecutive	cohort);	(2)	index	test	(low	risk	if	
the	assessment	of	PTEN	expression	was	based	on	objective	criteria);	
(3)	reference	standard	(low	risk	if	the	histologic	slides	were	reviewed	
to	confirm	the	 index	diagnosis);	 (4)	 flow	and	timing	 (low	risk	 if	 the	
latency	time	between	 index	and	reference	standard	did	not	affect	
the	results,	 if	all	patients	were	assessed	with	 the	same	tests,	 if	all	
patients	were	 assessed	with	 both	 index	 and	 reference	 standards).	
Review	 authors’	 judgments	 were	 categorized	 as	 “low	 risk,”	 “high	
risk,”	or	“unclear	risk”	of	bias.
Data	 from	 each	 eligible	 study	 were	 extracted	 without	 modi‐
fication	of	 the	original	 data.	 Two‐by‐two	 contingency	 tables	were	
prepared	 for	 each	 study,	 reporting	 two	 dichotomous	 qualitative	
variables:
1.	 PTEN	expression	 (“loss”	or	“presence”),	which	was	the	 index	test;
2.	 histological	diagnosis	(“precancerous”	or	“benign”),	which	was	the	
reference	standard.
Precancerous	cases	with	PTEN	loss	were	considered	as	true	posi‐
tives,	benign	cases	with	PTEN	presence	were	considered	as	true	neg‐
atives,	precancerous	 cases	with	PTEN	presence	were	considered	as	
false	negatives,	and	benign	cases	with	PTEN	loss	were	considered	as	
false	positives.
Data	regarding	the	 index	test	were	extracted	by	using	the	 fol‐
lowing	criteria:
1.	 for	 the	 studies	 dichotomizing	 PTEN	 expression	 (positive	 vs	
negative)	 independently	 from	 distribution	 and	 intensity	 of	 ex‐
pression,	 “negative”	 was	 considered	 as	 “PTEN	 loss”;
2.	 for	the	studies	using	a	semi‐quantitative	scale	to	grade	the	inten‐
sity	of	PTEN	expression,	independently	from	the	distribution,	the	
lowest	grade	(negative	expression)	was	considered	as	“PTEN	loss”;
3.	 for	the	studies	assessing	the	percentage	of	PTEN‐positive	glands,	
independently	from	the	intensity	of	staining,	the	lowest	percent‐
age	(negative	expression)	was	considered	as	“PTEN	loss.”
Data	regarding	the	reference	standard	were	extracted	by	using	the	
following	criteria:
1.	 for	the	studies	using	the	WHO	classification,	atypical	EH	(simple	
or	 complex)	 was	 considered	 as	 “precancer,”	 while	 EH	 without	
atypia	 (simple	 or	 complex)	 was	 considered	 as	 “benign”;
2.	 for	the	studies	using	the	EIN	classification,	endometrial	intraepi‐
thelial	neoplasia	or	high/intermediate‐risk	EH	 (D	≤	1)	were	con‐
sidered	 as	 “precancer,”	 while	 benign	 EH	 or	 low‐risk	 EH	 (D	<	1)	
were	considered	as	“benign”;
3.	 hyperproliferative	conditions	caused	by	unopposed	action	of	es‐
trogens	 (eg	 “disordered	 proliferative	 endometrium,”	 “persistent	
proliferative	endometrium”)	were	included	in	the	“benign”	group,	
as	proposed	in	the	literature,14	because	they	constitute	a	patho‐
logic	continuum	with	non‐atypical	EH.6
When	discrepancies	between	values	reported	in	the	text	and	the	
tables	were	found,	values	from	tables	were	used	for	the	analysis.	Data	
were	also	subdivided	into	two	subgroups	based	on	the	classification	
system	adopted	(WHO	vs	EIN).
Sensitivity,	 specificity,	 positive	 likelihood	 ratio	 (LR+),	 negative	
likelihood	ratio	 (LR−),	and	diagnostic	odds	 ratio	 (DOR)	were	calcu‐
lated	for	each	study	and	as	pooled	estimate	using	the	random	effect	
model	of	DerSimonian	and	Laird	and	reported	graphically	on	forest	
plots,	with	95%	CI.	Statistical	heterogeneity	among	studies	was	as‐
sessed	using	the	Higgins	 I2	statistic;	heterogeneity	was	considered	
insignificant	 for	 I2	<	25%,	 low	 for	 I2	<	50%,	moderate	 for	 I2	<	75%,	
and	high	for	I2	≥	75%.
Area	under	the	curve	(AUC)	was	calculated	on	summary	receiver	
operating	 characteristic	 (SROC)	 curves.	 The	 diagnostic	 usefulness	
was	 considered	 absent	 for	 AUC	≤	0.5,	 low	 for	 0.5	<	AUC	≤	0.75,	
moderate	for	0.75	<	AUC	≤	0.9,	high	for	0.9	<	AUC	<	0.97,	and	very	
high	for	AUC	≥	0.97.
As	 additional	 analysis,	we	performed	a	 subgroups	 analysis,	 as‐
sessing	sensitivity,	 specificity,	LR+,	LR−,	DOR,	and	AUC	separately	
for	the	two	subgroups.
The	 data	 analysis	 was	 performed	 using	 Review ManageR 5.3 
(Copenhagen:	The	Nordic	Cochrane	Center,	Cochrane	Collaboration,	
2014)	and	Meta‐DiSc	version	1.4	(Clinical	Biostatistics	Unit,	Ramon	y	
Cajal	Hospital,	Madrid,	Spain).
3  | RESULTS
We	 identified	 635	 articles	 through	 database	 searching	 and	 13	
through	 additional	 sources.	 After	 duplicate	 removal,	 189	 articles	
remained	and	101	were	screened.	Forty‐four	articles	were	consid‐
ered	relevant	and	so	were	assessed	for	eligibility;	17	of	them	were	
excluded	by	applying	our	exclusion	criteria.	Finally,	27	studies	were	
included	in	the	systematic	review,	18	of	which	were	suitable	for	the	
meta‐analysis.	Details	 about	 the	whole	process	of	 study	 selection	
are	shown	in	Figure	1.
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Twenty‐seven	 observational	 studies	were	 included	 in	 the	 sys‐
tematic	review:7,15‐40	19	adopted	the	WHO	classification	and	eight	
adopted	 the	 EIN	 classification.	 A	 total	 of	 1736	 cases	 of	 EH	were	
included;	 847	 (48.8%)	 EH	were	 classified	 as	 “precancer”	 and	 889	
(51.2%)	as	“benign.”	PTEN	loss	was	observed	in	443	of	847	(52.3%)	
premalignant	EH	and	299	of	889	(33.6%)	benign	EH.
Among	 the	1232	EH	classified	according	 to	 the	WHO	system,	
PTEN	loss	was	observed	in	336	of	593	(56.7%)	atypical	EH	and	221	
of	639	(34.6%)	non‐atypical	EH.
Among	the	504	EH	classified	according	to	the	EIN	system,	PTEN	
loss	was	observed	in	107	(42.1%)	of	254	premalignant	EH	and	in	78	
of	250	(31.2%)	benign	EH.
Fifteen	studies	dichotomized	PTEN	expression.	Six	studies	used	
an	intensity	scale	to	grade	PTEN	expression,	and	four	assessed	the	
percentage	of	PTEN‐positive	cells.	Three	studies	combined	 inten‐
sity	of	staining	and	percentage	of	stained	cells	to	obtain	a	staining	
score.
Details	about	characteristics	of	the	included	studies	and	methods	
for	immunohistochemistry	are	shown	in	Tables	1	and	2,	respectively.
Results	of	the	risk	of	bias	assessment	are	shown	in	Figure	2.	In	
particular,	 for	 the	 “patient	 selection”	 domain,	 three	 studies	 were	
classified	as	being	at	unclear	 risk	of	bias,	because	 they	 followed	a	
case–control	design;	nine	studies	were	considered	at	high	risk	of	bias	
because	they	selected	only	premalignant	EH.	All	the	remaining	stud‐
ies	were	considered	at	low	risk.
For	the	“index	test”	domain,	five	studies	were	considered	at	un‐
clear	risk	of	bias,	because	they	only	used	a	qualitative	scale	to	grade	
PTEN	expression,	regardless	of	the	percentage	of	stained	cells.	The	
other	studies	were	considered	at	low	risk.
For	the	“reference	standard”	domain,	17	studies	were	classified	
as	being	at	low	risk	of	bias,	because	they	specified	that	histological	
slides	were	reviewed	to	confirm	the	diagnosis	of	benign	or	premalig‐
nant.	The	other	10	studies	were	considered	at	unclear	risk.
For	the	“flow	and	timing”	domain,	all	the	included	studies	were	
classified	as	being	at	 low	risk	of	bias,	since	both	the	index	and	the	
reference	standard	were	performed	on	the	same	specimen	and	for	
all	patients.
Eighteen	studies	assessing	1362	EH	were	included	in	the	meta‐
analysis;7,15‐17,20,22,24‐27,29‐32,34,36‐38	(34.7%)	of	total	EH	were	prema‐
lignant	and	889	(65.3%)	were	benign.	The	nine	studies	not	assessing	
benign	EH	were	excluded	from	the	meta‐analysis.
Pooled	sensitivity	and	specificity	of	PTEN	loss	in	detecting	en‐
dometrial	precancer	were	54%	(95%	CI	50%‐59%)	and	66%	(95%	CI	
63%‐69%),	 respectively,	with	pooled	LR+	and	LR−	of	1.55	 (95%	CI	
1.29‐1.87)	 and	0.72	 (95%	CI	0.62‐0.83),	 respectively.	Pooled	DOR	
was	2.81	(95%	CI	1.96‐4.02).
Among	the	included	studies,	the	heterogeneity	was	high	in	sen‐
sitivity	(I2	=	80%)	and	specificity	(I2	=	92.5%),	low	in	LR+	(I2	=	43.2%),	
moderate	in	LR−	(I2	=	56.9%),	and	insignificant	in	DOR	(I2	=	23.5%).
The	 SROC	 curves	 analysis	 demonstrated	 low	 overall	 accuracy	
with	an	AUC	of	0.657.
Results	are	reported	graphically	in	forest	plots	and	SROC	curves	
in	Figure	3.
In	the	subgroup	analysis,	12	studies	assessing	934	EH	by	using	
the	WHO	system	were	 included	 in	 first	 subgroup;	 295	 (31.6%)	 of	
total	EH	were	premalignant	and	639	(68.4%)	were	benign.
Pooled	sensitivity	and	specificity	were	59%	(95%	CI	53%‐65%)	
and	 65%	 (95%	 CI	 62%‐69%),	 respectively,	 with	 pooled	 LR+	 and	
F I G U R E  1  Flow	diagram	of	studies	
identified	in	the	systematic	review	(Prisma	
template	[Preferred	Reporting	Item	for	
Systematic	Reviews	and	Meta‐analyses])
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LR−	of	1.56	(95%	CI	1.22‐1.98)	and	0.67	(95%	CI	0.52‐0.85),	respec‐
tively.	Pooled	DOR	was	3.56	(95%	CI	2.02‐6.28).
The	heterogeneity	was	high	in	sensitivity	(I2	=	81.4%)	and	speci‐
ficity	(I2	=	94.5%),	moderate	in	LR+	(I2	=	50.7%)	and	LR−	(I2	=	71.8%),	
and	low	in	DOR	(I2	=	30.1%).
The	 SROC	 curves	 analysis	 demonstrated	 low	 overall	 accuracy	
with	an	AUC	of	0.694.
Six	studies	assessing	428	EH	by	using	the	EIN	system	were	 in‐
cluded	in	the	second	subgroup;	178	(41.6%)	of	total	EH	were	prema‐
lignant	and	250	(58.4%)	were	benign.
Pooled	sensitivity	and	specificity	were	47%	(95%	CI	39%‐54%)	
and	69%	(95%	CI	63%‐74%),	respectively,	with	pooled	LR+	and	LR−	
of	1.59	(95%	CI	1.17‐2.17)	and	0.77	(95%	CI	0.67‐0.89),	respectively.	
Pooled	DOR	was	2.34	(95%	CI	1.47‐3.73).
The	heterogeneity	was	moderate	in	sensitivity	(I2	=	74.1%),	high	
in	specificity	(I2	=	79.9%),	low	in	LR+	(I2	=	27%),	and	completely	ab‐
sent	in	LR−	(I2	=	0%)	and	DOR	(I2	=	0%).
The	 SROC	 curves	 analysis	 demonstrated	 low	 overall	 accuracy	
with	an	AUC	of	0.621.
Results	are	reported	graphically	in	forest	plots	and	SROC	curves	
for	the	WHO	and	EIN	subgroups,	respectively	in	Figures	4	and	5.
4  | DISCUSSION
Although	a	loss	of	PTEN	function	is	involved	in	endometrial	carcino‐
genesis,	our	study	showed	that	immunohistochemical	evaluation	of	
PTEN	expression	has	a	low	diagnostic	usefulness	in	the	differential	
diagnosis	between	benign	and	premalignant	EH.
The	PTEN	gene	 is	 located	at	chromosome	10q23	and	encodes	
a	phosphatase	that	acts	as	a	tumor	suppressor.	 It	has	a	 lipid	phos‐
phatase	 activity,	 which	 induces	 cell	 cycle	 arrest,	 upregulates	
AKT‐dependent	 pro‐apoptotic	 mechanisms	 and	 downregulates	
Bcl‐2‐dependent	 anti‐apoptotic	 mechanisms,	 acting	 in	 opposition	
TA B L E  2  Methods	for	immunohistochemistry	in	each	included	study
Year First author (ref)
Antibody Incubation
Vendor Clone Time Temperature Dilution
2000 Mutter	7 Not	reported 6H2.1 1	h Room	temperature 1:100
2001 Mutter	15 Cascade	Biosciences 6H2.1 Overnight 4°C 1:300
2003 Ørbo 16 Santa	Cruz	
Biotechnology
A2B1 30 min Room	temperature 1:50
2005 Baak	17 Cascade	Biosciences 6H2.1 30 min Not	reported 1:300
2006 Cirpan	18 Novocastra 28H6 30 min Not	reported Not	reported
McCampbell	19 Cascade	Biosciences 6H2.1 Overnight 4°C 1:50
2007 Kapucuoglu	20 LabVision 17.A 1	h Not	reported 1:50
Minaguchi	21 Santa	Cruz	
Biotechnology
A2B1 Overnight 4°C 1:50
Norimatsu	22 Cascade	Biosciences 6H2.1 Not	reported Not	reported 1:100
2008 Chen	23 Antibody	Diagnostica Not	reported 1	h Not	reported 1:60
Lacey	24 Cascade	Biosciences 6H2.1 Overnight 4°C 1:300
Tantbirojn	25 Cascade	Biosciences 6H2.1 1	h Room	temperature 1:100
2009 Abd	El‐Masqoud	26 LabVision 28H6 Not	reported Not	reported 1:100
Sarmadi	27 Zymed	Laboratories Polyclonal 60 min Not	reported 1:100
2010 Monte	28 Dako 6H2.1 Overnight 4°C 1:100
Pavlakis	29 Cascade	Biosciences 6H2.1 Overnight 4°C 1:300
Xiong 30 Maixin	Bio Not	reported Not	reported Not	reported Not	reported
2011 Pieczynska	31 Novocastra Not	reported 1.5	h Room	temperature 1:800
Rao 32 Biogenex 28H6 Not	reported Not	reported Not	reported
2012 Feng	33 Antibody	Diagnostica Not	reported 1	h 37°C 1:60
Lee	34 Cell	Signaling	Technology 138G6 Not	reported Not	reported 1:100
Robbe 35 Not	reported Not	reported 30 min Room	temperature Not	reported
Upson	36 Cascade	Biosciences 6H2.1 40 min Room	temperature 1:100
2013 Huang	37 Dako 6H2.1 Not	reported Not	reported 1:100
2014 Shawana	38 Millipore 6H2.1 1	h Room	temperature 1:50
2015 Ayhan	39 Dako 6H2.1 Not	reported Not	reported 1:100
Berg	40 Cell	Signaling #9188 Overnight 4°C 1:100
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to	phosphatidylinositol	3‐kinase	(PI3K).	Moreover,	PTEN	has	also	a	
protein	phosphatase	activity,	which	 is	 involved	 in	 the	 inhibition	of	
focal	adhesion	formation,	cell	spread,	and	growth‐factor‐stimulated	
mitogen‐activated	protein	kinase	(MAPK)	signaling.41
In	 the	 four	 categories	 of	 endometrial	 cancer	 identified	 by	 the	
Cancer	Genome	Atlas	Research	Network	 (ultramutated,	hypermu‐
tated,	copy	number	low,	copy	number	high),	PTEN	mutations	were	
found	in	94%,	88%,	77%,	and	15%	of	cases,	respectively.8
According	to	our	results,	the	immunohistochemical	assessment	
of	 PTEN	 has	 a	 low	 diagnostic	 usefulness,	 as	 demonstrated	 by	 an	
AUC	<	0.75	(0.657).
Such	 a	 test	would	 determine	which	women	 should	 be	 treated	
to	prevent	cancer,	so	a	high	sensitivity	appears	crucial	in	order	not	
to	miss	patients	at	risk.	For	this	reason,	a	sensitivity	of	59%	appears	
to	be	not	enough.	On	the	other	hand,	as	hysterectomy	is	the	refer‐
ence	standard	intervention	for	premalignant	EH,	a	high	specificity	is	
also	needed	 to	avoid	severe	overtreatment.	Hence,	 the	specificity	
observed	(66%)	is	too	low.	Given	these	findings,	PTEN	assessment	
appears	inadequate	as	a	stand‐alone	diagnostic	test.
However,	 a	 suboptimal	 sensitivity	might	be	expected,	because	
not	 all	 endometrioid	 adenocarcinomas	 or	 their	 precursor	 lesions	
have	underlying	mutations	of	the	PTEN	gene.8,9
Concerning	 the	 low	 specificity,	 a	 possible	 cause	may	be	 that	 a	
loss	 of	 PTEN	expression	 does	 not	 necessarily	 indicate	 a	monoclo‐
nal	 lesion.	 In	 fact,	Yilmaz	et	al	observed	PTEN	 loss	using	 immuno‐
histochemistry	 in	3/36	 (8.3%)	polyclonal	 endometrial	 specimens.42 
Furthermore,	a	loss	of	PTEN	expression	may	be	observed	in	morpho‐
logically	normal	clones	of	endometrial	glands,	which	tend	to	spon‐
taneously	regress.	Mutter	et	al	showed	that	only	a	small	proportion	
(6.7%)	of	these	latent	precancers	actually	progress	to	overt	lesions.43
In	 the	WHO	 subgroup,	 higher	 sensibility	 and	DOR,	 and	 lower	
specificity,	LR+,	and	LR−,	were	found	when	compared	with	the	EIN	
subgroup.	This	 resulted	 in	 a	 greater	AUC	 for	 the	WHO	subgroup.	
The	heterogeneity	was	higher	in	the	WHO	subgroup	for	all	analyses,	
possibly	because	of	the	better	reproducibility	of	the	EIN	system.2,3 
In	a	comparison	study,	 the	prognostic	ability	of	 the	two	classifica‐
tions	appeared	to	be	superimposable.14
A	possible	cause	of	both	the	higher	diagnostic	accuracy	and	the	
heterogeneity	for	the	WHO	subgroup	may	be	found	 in	the	“small‐
study	effect.”	Nonetheless,	a	meta‐epidemiological	study	published	
in	2014	showed	that	such	an	effect	was	not	significant	in	meta‐anal‐
yses	of	diagnostic	test	accuracy.44
To	the	best	of	our	knowledge,	this	study	is	the	first	meta‐anal‐
ysis	 assessing	 the	 usefulness	 of	 the	 immunohistochemical	 evalua‐
tion	of	PTEN	in	the	differential	diagnosis	between	premalignant	and	
benign	EH.	Most	of	the	included	studies	only	assessed	the	associa‐
tion	between	PTEN	loss	and	premalignant	features	of	EH,	without	
F I G U R E  2  A,	Assessment	of	risk	of	bias.	Summary	of	risk	of	bias	
for	each	study.	Plus	sign:	low	risk	of	bias;	minus	sign:	high	risk	of	
bias;	question	mark:	unclear	risk	of	bias.	B,	Risk	of	bias	graph	about	
each	risk	of	bias	item	presented	as	percentages	across	all	included	
studies	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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evaluating	the	diagnostic	accuracy	of	PTEN.	We	aimed	to	define	the	
actual	diagnostic	usefulness	of	PTEN	assessment	in	EH.	As	current	
guidelines	recommending	evaluation	of	PTEN	loss	are	based	on	level	
IV	evidence,10	a	meta‐analysis	can	provide	a	higher	level	of	evidence	
for	future	recommendations.	The	current	study	provides	both	new	
and	important	insights	into	the	field.
Major	limitations	to	our	results	might	be	the	intra‐	and	inter‐ob‐
server	variability	for	both	 index	test	and	reference	standard.	Such	
F I G U R E  3  Forest	plots	of	individual	studies	and	pooled	sensitivity	(A),	specificity	(B),	positive	likelihood	ratio	(C),	negative	likelihood	
ratio	(D),	and	diagnostic	odds	ratio	(E)	of	PTEN	immunohistochemical	assessment	in	differential	diagnosis	between	benign	and	premalignant	
endometrial	hyperplasia,	with	summary	receiver	operating	characteristic	curves	(F)	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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variability	may	explain	the	high	heterogeneity	observed	for	sensitiv‐
ity	and	specificity	analysis.
Concerns	 about	 the	 index	 text	 regard	 the	 lack	 of	 standard‐
ized	 and	 objective	 criteria	 for	 interpreting	 PTEN	 immunostaining.	
However,	 it	 was	 shown	 that	 a	 subjective	 categorization	 of	 PTEN	
immunostaining	as	“normal,”	“heterogeneous,”	or	“loss,”	was	highly	
reproducible.45
Regarding	the	reference	standard,	well‐described	concerns	relate	
to	the	variability	in	the	histologic	criteria.	In	particular,	the	diagnosis	
of	cytologic	atypia	has	shown	poor	reproducibility.2,46	Furthermore,	
the	characteristics	of	atypia	specific	for	endometrial	epithelium	are	
not	included	in	the	WHO	classification	system,	and	metaplastic	and	
regenerative	 changes	may	mimic	 true	 atypia.1,6,46	Other	 concerns	
refer	to	the	fact	that	premalignant	hyperplasia	is	a	focal	change,1‐3,47 
and	the	amount	of	tissue/cells	harboring	the	atypical	features	may	
be	scant,	particularly	in	aspiration	biopsies	or	curettage	samples.2,6 
In	addition,	the	degree	of	atypia	is	often	variable,	further	complicat‐
ing	the	determination	of	diagnostic	atypia.46	As	discussed,	the	2014	
F I G U R E  4  Forest	plots	of	individual	studies	and	pooled	sensitivity	(A),	specificity	(B),	positive	likelihood	ratio	(C),	negative	likelihood	
ratio	(D),	and	diagnostic	odds	ratio	(E)	of	PTEN	immunohistochemical	assessment	in	differential	diagnosis	between	benign	and	premalignant	
endometrial	hyperplasia,	with	summary	receiver	operating	characteristic	curves	(F),	for	the	World	Health	Organization	subgroup	[Color	
figure	can	be	viewed	at	wileyonlinelibrary.com]
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revision	of	the	WHO	classification	has	tried	to	improve	the	diagnos‐
tic	criteria	by	referring	to	the	EIN	system.	Such	revised	classification	
uses	“EIN”	as	a	synonym	of	atypical	EH.1	However,	WHO	2014	terms	
might	be	confounding	because	the	acronym	“EIN”	refers	to	“endo‐
metrioid	intraepithelial	neoplasia.”	It	is	therefore	unclear	if	it	actually	
relates	 to	 the	EIN	 (endometrial	 intraepithelial	neoplasia)	classifica‐
tion.	 In	spite	of	such	revision,	 the	WHO	classification	still	appears	
to	be	based	on	the	presence	of	cytologic	atypia.1	Unfortunately,	we	
were	not	able	to	consider	the	2014	WHO	classification	separately	
from	the	former	versions,	because	of	the	lack	of	studies	published	
after	2014	in	the	WHO	subgroup.
In	our	opinion,	 further	 studies	 in	 this	 field	 should	 improve	 the	
reliability	of	both	the	index	test	and	the	reference	standard.
The	reliability	of	the	index	test	might	be	improved	by	standard‐
izing	 criteria	 for	 interpreting	 PTEN	 immunostaining,	 in	 terms	 of	
intensity	of	staining	and	percentage	of	stained	cells.	The	antibody	to	
be	used	should	also	be	standardized.	Among	the	available	anti‐PTEN	
antibodies,	it	is	unclear	which	one	should	be	used.	In	fact,	the	clone	
6H21	was	used	in	the	study	showing	the	highest	DOR,38 as well as in 
the	one	showing	the	lowest	DOR.29	A	study	published	in	2011	sug‐
gested	the	clone	138G6	to	be	the	most	reliable.48	In	our	systematic	
review,	 the	only	 study	using	 such	a	 clone	was	not	 included	 in	 the	
meta‐analysis	because	of	the	lack	of	a	control	group	of	benign	EH.34
On	the	other	hand,	the	reliability	of	the	reference	standard	might	
be	partially	improved	through	consensus	among	several	pathologists	
in	the	evaluation	of	histologic	slides.	A	combination	of	several	mark‐
ers	more	specific	than	PTEN	(such	as	Bcl‐249)	might	considerably	re‐
duce	the	variability	of	the	reference	standard.
However,	given	the	limitations	inherent	to	PTEN	and	discussed	
above,	 it	 is	probable	that	 the	diagnostic	usefulness	of	PTEN	alone	
F I G U R E  5  Forest	plots	of	individual	studies	and	pooled	sensitivity	(A),	specificity	(B),	positive	likelihood	ratio	(C),	negative	likelihood	
ratio	(D),	and	diagnostic	odds	ratio	(E)	of	PTEN	immunohistochemical	assessment	in	differential	diagnosis	between	benign	and	premalignant	
endometrial	hyperplasia,	with	summary	receiver	operating	characteristic	curves	(F),	for	the	endometrial	intraepithelial	neoplasia	subgroup	
[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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might	be	fair	at	best,	even	with	optimized	criteria.	Further	studies	
appear	 necessary	 to	 clarify	 the	 prognostic	 value	 of	 PTEN	 immu‐
nohistochemistry	 in	EH,	with	specific	 regard	to	the	progression	to	
cancer.
5  | CONCLUSION
Although	 a	 loss	 of	 PTEN	 expression	 was	 associated	 with	 endo‐
metrial	precancer,	 immunohistochemistry	 for	PTEN	showed	a	 low	
diagnostic	usefulness	 in	the	differential	diagnosis	between	benign	
and	premalignant	EH,	independently	from	the	histologic	classifica‐
tion	 used	 (WHO	or	 EIN).	 In	 the	 absence	 of	 further	 evidence,	 the	
recommendation	about	the	use	of	PTEN	for	this	purpose	should	be	
reconsidered.
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